Cargando…

The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats

The dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) has been used as an effective drug for treating dopamine depletion-induced Parkinson’s disease (PD). However, long-term administration of L-DOPA produces motor complications. L-DOPA has also been found to modify the two key signaling casca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Lu, Yang, Xinxin, Ma, Yaping, Wu, Na, Liu, Zhenguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226453/ https://www.ncbi.nlm.nih.gov/pubmed/25395834 http://dx.doi.org/10.2147/DDDT.S60944

Ejemplares similares

Temporal Changes of CB1 Cannabinoid Receptor in the Basal Ganglia as a Possible Structure-Specific Plasticity Process in 6-OHDA Lesioned Rats
por: Chaves-Kirsten, Gabriela P., et al.
Publicado: (2013)

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
por: Yang, Xinxin, et al.
Publicado: (2012)

Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
por: Lu, Di-Sheng, et al.
Publicado: (2018)

Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG‐018
por: Finlay, David B., et al.
Publicado: (2022)

Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence
por: Ibsen, Mikkel Søes, et al.
Publicado: (2019)

Cannabinoid 1 (CB(1)) receptor arrestin subtype‐selectivity and phosphorylation dependence
por: Manning, Jamie J., et al.
Publicado: (2022)

Corrigendum: Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
por: Lu, Di-Sheng, et al.
Publicado: (2020)

Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity
por: Franks, Lirit N., et al.
Publicado: (2016)

Evaluation of carboxamide-type synthetic cannabinoids as CB(1)/CB(2) receptor agonists: difference between the enantiomers
por: Doi, Takahiro, et al.
Publicado: (2017)

On the Role of Cannabinoid CB1- and μ-Opioid Receptors in Motor Impulsivity
por: Wiskerke, Joost, et al.
Publicado: (2012)

Cannabinoid CB1 receptor agonist ACEA alleviates brain ischemia/reperfusion injury via CB1–Drp1 pathway
por: Yang, Shuai, et al.
Publicado: (2020)

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB(2) receptor
por: Patel, Monica, et al.
Publicado: (2023)

Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist
por: Polini, Beatrice, et al.
Publicado: (2020)

Cannabinoid CB(1) and CB(2) Receptor Signaling and Bias
por: Ibsen, Mikkel Søes, et al.
Publicado: (2017)

Cannabigerol Action at Cannabinoid CB(1) and CB(2) Receptors and at CB(1)–CB(2) Heteroreceptor Complexes
por: Navarro, Gemma, et al.
Publicado: (2018)

Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson’s disease
por: Kamińska, Kinga, et al.
Publicado: (2022)

The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson’s Disease
por: Yu, Hao, et al.
Publicado: (2021)

Vascular Dysfunction in a Transgenic Model of Alzheimer's Disease: Effects of CB1R and CB2R Cannabinoid Agonists
por: Navarro-Dorado, Jorge, et al.
Publicado: (2016)

Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions
por: Lakiotaki, Eleftheria, et al.
Publicado: (2015)

Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson’s disease mouse model
por: Doo, Ah-Reum, et al.
Publicado: (2014)

Effects of the cannabinoid CB(1) agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus in guinea pigs
por: Berger, Joel I., et al.
Publicado: (2017)

L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats
por: Huang, Yixian, et al.
Publicado: (2018)

Fucoxanthin Prevents Long-Term Administration l-DOPA-Induced Neurotoxicity through the ERK/JNK-c-Jun System in 6-OHDA-Lesioned Mice and PC12 Cells
por: Liu, Jingwangwei, et al.
Publicado: (2022)

Cannabinoid CB1 receptors regulate salivation
por: Andreis, Kelsey, et al.
Publicado: (2022)

Voltage dependence of the cannabinoid CB1 receptor
por: Goldberger, Esty, et al.
Publicado: (2022)

The Structure–Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation
por: Bow, Eric W., et al.
Publicado: (2016)

Expression and Function of Cannabinoid Receptors CB1 and CB2 and Their Cognate Cannabinoid Ligands in Murine Embryonic Stem Cells
por: Jiang, Shuxian, et al.
Publicado: (2007)

Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson’s Disease
por: dos Santos Pereira, Maurício, et al.
Publicado: (2021)

CB2 Agonist GW842166x Protected against 6-OHDA-Induced Anxiogenic- and Depressive-Related Behaviors in Mice
por: Liu, Xiaojie, et al.
Publicado: (2022)

CB(1) Allosteric Modulator Org27569 Is an Antagonist/Inverse Agonist of ERK1/2 Signaling
por: Gamage, Thomas F., et al.
Publicado: (2016)

Cannabinoid Receptors CB1 and CB2 Modulate the Electroretinographic Waves in Vervet Monkeys
por: Bouskila, Joseph, et al.
Publicado: (2016)

CB1 Cannabinoid Receptor Signaling and Biased Signaling
por: Leo, Luciana M., et al.
Publicado: (2021)

Cannabinoid CB(1) Receptor Agonists Do Not Decrease, but may Increase Acoustic Trauma-Induced Tinnitus in Rats
por: Zheng, Yiwen, et al.
Publicado: (2015)

CB(1) Cannabinoid Receptors Stimulate Gβγ-GRK2-Mediated FAK Phosphorylation at Tyrosine 925 to Regulate ERK Activation Involving Neuronal Focal Adhesions
por: Dalton, George D., et al.
Publicado: (2020)

Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats
por: Sgroi, Stefania, et al.
Publicado: (2014)

Effects of pro‐inflammatory cytokines on cannabinoid CB (1) and CB (2) receptors in immune cells
por: Jean‐Gilles, L., et al.
Publicado: (2015)

Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms
por: Soderstrom, Ken, et al.
Publicado: (2017)

Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway
por: Yan, Aijuan, et al.
Publicado: (2021)

Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats
por: Xie, Cheng-long, et al.
Publicado: (2014)

Cannabinoid(1) (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose
por: Skolnick, Phil, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q5dm8vmp019hsm3co350iqmg58